Immune Reconstitution in Chronic Lymphocytic Leukemia

被引：26
作者：
Riches, John C. [1 ]
Ramsay, Alan G. [1 ]
Gribben, John G. [1 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, John Vane Sci Ctr, London EC1M 6BQ, England
来源：
CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2012年 / 7卷 / 01期
关键词：
Chronic lymphocytic leukemia; CLL; Immune suppression; Immune reconstitution; CD40; ligand; Gene therapy; Lenalidomide; Chimeric antigen receptor; Adoptive T-cell therapies; CHIMERIC ANTIGEN RECEPTOR; REGULATORY T-CELLS; B-CELLS; PHASE-I; UP-REGULATION; GENE-THERAPY; LENALIDOMIDE; EXPRESSION; CLL; ACTIVATION;
D O I：
10.1007/s11899-011-0106-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chronic lymphocytic leukemia (CLL) is associated with a profound immune defect, which results in increased susceptibility to recurrent infections as well as a failure to mount effective antitumor immune responses. Current chemotherapy-based regimens are not curative and often worsen this immune suppression, so their usefulness is limited, particularly in the frail and elderly. This article reviews the immune defect in CLL and discusses strategies aimed at repairing or circumventing this defect. In particular, it focuses on recent developments in the areas of CD40 ligand (CD40L/CD154) gene therapy, immunomodulatory agents such as lenalidomide, and adoptive transfer of T cells bearing chimeric antigen receptors.
引用
收藏
页码：13 / 20
页数：8
相关论文
共 81 条
  • [1] The silent war against CMV in CLL
    Akbar, Arne N.
    [J]. BLOOD, 2010, 116 (16) : 2869 - 2870
  • [2] Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
    Andritsos, Leslie A.
    Johnson, Amy J.
    Lozanski, Gerard
    Blum, William
    Kefauver, Cheryl
    Awan, Farrukh
    Smith, Lisa L.
    Lapalombella, Rosa
    May, Sarah E.
    Raymond, Chelsey A.
    Wang, Da-Sheng
    Knight, Robert D.
    Ruppert, Amy S.
    Lehman, Amy
    Jarjoura, David
    Chen, Ching-Shih
    Byrd, John C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2519 - 2525
  • [3] In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor
    Attianese, Greta Maria Paola Giordano
    Marin, Virna
    Hoyos, Valentina
    Savoldo, Barbara
    Pizzitola, Irene
    Tettamanti, Sarah
    Agostoni, Valentina
    Parma, Matteo
    Ponzoni, Maurilio
    Bertilaccio, Maria T. S.
    Ghia, Paolo
    Biondi, Andrea
    Dotti, Gianpietro
    Biagi, Ettore
    [J]. BLOOD, 2011, 117 (18) : 4736 - 4745
  • [4] Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
    Aue, Georg
    Njuguna, Ndegwa
    Tian, Xin
    Soto, Susan
    Hughes, Thomas
    Vire, Berengere
    Keyvanfar, Keyvan
    Gibellini, Federica
    Valdez, Janet
    Boss, Carol
    Samsel, Leigh
    McCoy, J. Philip, Jr.
    Wilson, Wyndham H.
    Pittaluga, Stefania
    Wiestner, Adrian
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (09): : 1266 - 1273
  • [5] Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wen, Sijin
    Lee, Bang-Ning
    Sivina, Mariela
    Reuben, James
    Wierda, William G.
    O'Brien, Susan M.
    Faderl, Stefan
    Kornblau, Steven M.
    Burger, Jan A.
    Ferrajoli, Alessandra
    [J]. BLOOD, 2011, 118 (13) : 3489 - 3498
  • [6] Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
    Beyer, M
    Kochanek, M
    Darabi, K
    Popov, A
    Jensen, M
    Endl, E
    Knolle, PA
    Thomas, RK
    von Bergwelt-Baildon, M
    Bebey, S
    Hallek, M
    Schultze, JL
    [J]. BLOOD, 2005, 106 (06) : 2018 - 2025
  • [7] Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
    Boissel, Laurent
    Betancura, Monica
    Wels, Winfried S.
    Tuncer, Hande
    Klingemann, Hans
    [J]. LEUKEMIA RESEARCH, 2009, 33 (09) : 1255 - 1259
  • [8] Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
    Brentjens, Renier
    Yeh, Raymond
    Bernal, Yvette
    Riviere, Isabelle
    Sadelain, Michel
    [J]. MOLECULAR THERAPY, 2010, 18 (04) : 666 - 668
  • [9] Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
    Brentjens, RJ
    Latouche, JB
    Santos, E
    Marti, F
    Gong, MC
    Lyddane, C
    King, PD
    Larson, S
    Weiss, M
    Rivière, I
    Sadelain, M
    [J]. NATURE MEDICINE, 2003, 9 (03) : 279 - 286
  • [10] Brentjens RJ, 2011, BLOOD
123456789